Literature DB >> 17170049

Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

Wilco de Jager1, Esther P A H Hoppenreijs, Nico M Wulffraat, Lucy R Wedderburn, Wietse Kuis, Berent J Prakken.   

Abstract

BACKGROUND: Juvenile idiopathic arthritis (JIA) consists of a heterogeneous group of disorders with, for the most part, an unknown immunopathogenesis. Although onset and disease course differ, the subtypes of JIA share the occurrence of chronic inflammation of the joints, with infiltrations of immunocompetent cells that secrete inflammatory mediators.
OBJECTIVE: To identify a panel of cytokines specifically related to the inflammatory process in JIA.
METHODS: Using a new technology, the multiplex immunoassay, 30 cytokines were measured in plasma of 65 patients with JIA, of which 34 were paired with synovial fluid. These data were compared with plasma of 20 healthy controls and 9 patients with type I diabetes, a chronic inflammatory disease.
RESULTS: Patients with JIA had, irrespective of their subclassification, significantly higher levels of tumour necrosis factor alpha, macrophage inhibitory factor (MIF), CCL2, CCL3, CCL11, CCL22 and CXCL9 in plasma than controls. In paired plasma and synovial fluid samples of patients with JIA, significantly higher levels of interleukin (IL)6, IL15, CCL2, CCL3, CXCL8, CXCL9 and CXCL10 were present in synovial fluid. Cluster analysis in all patients with JIA revealed a predominant pro-inflammatory cytokine cluster during active disease and a regulatory/anti-inflammatory-related cytokine cluster during remission. Whether a discrimination profile of various cytokines could help in the determination of disease classification was tested.
CONCLUSION: It is suggested that several cytokines (IL18, MIF, CCL2, CCL3, CCL11, CXCL9 and CXCL10) may correspond to the activation status during inflammation in JIA and could be instrumental in monitoring disease activity and outcomes of (new) immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17170049      PMCID: PMC1954617          DOI: 10.1136/ard.2006.061853

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  58 in total

1.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

2.  Interleukin-1, -6, and -8 levels in juvenile chronic arthritis.

Authors:  S Ozen; U Saatci; A Bakkaloglu; O Ozdemir; N Besbas; S Kirazli; S Ozdemir
Journal:  Clin Rheumatol       Date:  1997-03       Impact factor: 2.980

3.  Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model.

Authors:  D A Barnes; J Tse; M Kaufhold; M Owen; J Hesselgesser; R Strieter; R Horuk; H D Perez
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

Review 4.  Chemokines--chemotactic cytokines that mediate inflammation.

Authors:  A D Luster
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

Review 5.  Chemokines and leukocyte traffic.

Authors:  M Baggiolini
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

Review 6.  Cytokines in juvenile rheumatoid arthritis.

Authors:  F De Benedetti; A Ravelli; A Martini
Journal:  Curr Opin Rheumatol       Date:  1997-09       Impact factor: 5.006

Review 7.  Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis.

Authors:  Shumpei Yokota
Journal:  Curr Opin Rheumatol       Date:  2003-09       Impact factor: 5.006

8.  Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications.

Authors:  N Petrovsky; P McNair; L C Harrison
Journal:  Cytokine       Date:  1998-04       Impact factor: 3.861

9.  High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130.

Authors:  P Pignatti; L Ciapponi; P Galle; M B Hansen; M Massa; C Meazza; G Paonessa; D Novick; G Ciliberto; A Martini; F De Benedetti
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

10.  Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis.

Authors:  L Lepore; M Pennesi; S Saletta; S Perticarari; G Presani; M Prodan
Journal:  Clin Exp Rheumatol       Date:  1994 Sep-Oct       Impact factor: 4.473

View more
  109 in total

1.  Protective effect of eotaxin-2 inhibition in adjuvant-induced arthritis.

Authors:  J N Ablin; M Entin-Meer; V Aloush; S Oren; O Elkayam; J George; I Barshack
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  [Biomarkers for chronic inflammatory diseases].

Authors:  D Holzinger; D Föll
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

3.  Alternative activation in systemic juvenile idiopathic arthritis monocytes.

Authors:  Claudia Macaubas; Khoa D Nguyen; Ariana Peck; Julia Buckingham; Chetan Deshpande; Elizabeth Wong; Heather C Alexander; Sheng-Yung Chang; Ann Begovich; Yue Sun; Jane L Park; Kuang-Hung Pan; Richard Lin; Chih-Jian Lih; Erin M Augustine; Carolyn Phillips; Andreas V Hadjinicolaou; Tzielan Lee; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2011-12-28       Impact factor: 3.969

4.  Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra.

Authors:  Loes M Kuijk; Anita M A P Govers; Joost Frenkel; Willem J D Hofhuis
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

5.  Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation.

Authors:  Diane D Shao; Rahul Suresh; Varsha Vakil; Richard H Gomer; Darrell Pilling
Journal:  J Leukoc Biol       Date:  2008-03-10       Impact factor: 4.962

6.  Obstructive sleep apnea, excessive daytime sleepiness, and morning plasma TNF-α levels in Greek children.

Authors:  Emmanouel I Alexopoulos; Vasiliki Theologi; Georgia Malakasioti; Panagiotis Maragozidis; Irene Tsilioni; George Chrousos; Konstantinos Gourgoulianis; Athanasios G Kaditis
Journal:  Sleep       Date:  2013-11-01       Impact factor: 5.849

7.  CXCL10 is upregulated in synovium and cartilage following articular fracture.

Authors:  Bridgette D Furman; Collin L Kent; Janet L Huebner; Virginia B Kraus; Amy L McNulty; Farshid Guilak; Steven A Olson
Journal:  J Orthop Res       Date:  2017-11-20       Impact factor: 3.494

8.  Thrombospondin-1 and transforming growth factor beta are pro-inflammatory molecules in rheumatoid arthritis.

Authors:  Mario C Rico; Joanne M Manns; Jeffrey B Driban; Audrey B Uknis; Satya P Kunapuli; Raul A Dela Cadena
Journal:  Transl Res       Date:  2008-07-11       Impact factor: 7.012

9.  Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers.

Authors:  Kiran Nistala; Halima Moncrieffe; Katy R Newton; Hemlata Varsani; Patricia Hunter; Lucy R Wedderburn
Journal:  Arthritis Rheum       Date:  2008-03

10.  Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays.

Authors:  Wilco de Jager; Katarzyna Bourcier; Ger T Rijkers; Berent J Prakken; Vicki Seyfert-Margolis
Journal:  BMC Immunol       Date:  2009-09-28       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.